Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 15, 1999, Pages 2259-2262

  Kaltenbach III, Robert F ^a   Klabe, Ronald M ^a   Cordova, Beverly C ^a   Seitz, Steven P ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Antiproliferative agents; Antivirals; Enzyme inhibitors; Substituent effects

Indexed keywords

1 (3 AMINO 5 INDAZOLYL) 4,7 DIBENZYL 3 BUTYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 2H 1,3 DIAZEPIN 2 ONE; DMP 850; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; LIPOPHILICITY; NONHUMAN; PROTEINASE INHIBITION;

DRUG DESIGN; HIV PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 0033517017     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00367-4     Document Type: Article

References (12)

1. (a) Vacca, J. P.; Condra, J. H. Drug Discovery Today 1997, 2, 261.
2. (b) Danner, S. A.; Carr, A.; Leonard, J. M; Leman, L. M.; Gudiol, F.; Gonzales, J.; Raventos, A.; Rubio, R.; Bouza, E.; Pintado, V.; Aguado, A. G.; De Lomas, J. G.; Delgado, R.; Borleffs, J. C. C.; Hsu, A.; Valdes, J. M.; Boucher, C. A. B.; Cooper, D. A. N. Engl. J. Med. 1995, 333, 1528.
3. (c) Markowitz, M.; Saag, M.; Powderly, W. G.; Hurley, A. M.; Hsu, A.; Valdes, J. M.; Henry, D.; Sattler, F.; La Marca, A.; Leonard, J. M.; Ho, D. D. N. Eng. J. Med. 1995, 333, 1534.
4. (c) Kitchen, V. S.; Skinner, C.; Ariyoshi, K.; Lane, E. A.; Duncan, I. B.; Burckhardt, J.; Burger, H. U.; Bragman, K.; Pinching, A. J.; Weber, J. N. The Lancet 1995, 345, 952.
5. Rodgers, J. D.; Lam, P. Y. S.; Johnson, B. L.; Wang, H.; Ko, S. S.; Seitz, S. P.; Trainor, G. L.; Anderson, P. S.; Klabe, R. M.; Bacheler, L. T.; Cordova, B. C.; Garber, S.; Reid, C.; Wright, M. R.; Chang, C-H.; Erickson-Viitanen, S. Chemistry & Biology 1998, 5, 597.
6. Rodgers, J. D.; Johnson, B. L.; Wang, H.; Erickson-Viitanen, S.; Klabe, R. M.; Bacheler, L.; Cordova, B. C.; Chang, C-H. Bioorg. Med. Chem. Lett. 1998, 8, 715.
7. Poor translation has usually been attributed to the inability of highly polar compounds to penetrate cell membranes however numerous other parameters must be considered including lipid solubility, binding to media, compound stability and intracellular localization.
8. Nugiel, D. A.; Jacobs, K.; Worley, T.; Patel, M.; Kaltenbach III, R. F.; Meyer, D. T.; Jadhav, P. K.; DeLucca, G. V.;. Smyser, T. E.; Klabe, R. M.; Bacheler, L. T.; Rayner, M. M.; Seitz, S. P. J. Med. Chem. 1996, 39, 2156.
9. Erickson-Viitanen, S.; Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Antimicrob. Agents Chemother. 1994, 38, 1628.
10. Bacheler, L. T.; Paul, M.; Jadhav, P. K.; Otto, M.; Stone, B.; Miller, J. Antiviral Chem. Chemo. 1994, 5(2), 111.
11. Computer generated Clog P was calculated using MedChem Software Release 3.32, Ponoma College, Claremont, Ca.
12. Correlation coefficient = 0.67.